Quality by Design (QbD) in Pharmaceutical Development
Quality by Design (QbD) is at the very heart of modern pharmaceutical development. The implementation of QbD principles provides cost-efficient approach for delivering high quality medicines for patients. Regulatory authorities - both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) - are placing great emphasis on the QbD component as a part of regulatory filing. QbD has become a crucial element of a stream-lined drug development process.
This course will provide an insight into the key principles of
QbD covering quality risk management, formal experimental design
and process analytical technology (PAT). Leading QbD experts – from
industry, regulatory and academic side – will introduce the current
knowledge on QbD and provide participants with ideas how this
knowledge can be implemented in your company. The course includes
The course will provide a thorough introduction to the underlying principles and tools required for QbD-based pharmaceutical development and manufacturing:
- Basic risk analysis techniques
- Constructing the quality target product profile (QTPP)
- Identification of critical quality attributes (CQAs) and critical process parameters (CPPs)
- Design of Experiments (DoE): Basic screening designs, expanded designs
- Process Analytical Technologies (PAT): basic principles of chemometrics, purpose of process measurements in pharmaceutical development and manufacturing, examples of process measurement techniques
- Risk based regulatory framework.
Master's Programme in Industrial Drug Development - elective
The course is intended as continuing professional development (CPD) for professionals in the pharmaceutical industry, particularly in production, regulatory affairs and quality functions. The course will be an excellent introduction for those less familiar with QbD and will provide those with more experience on QbD with new ideas on how to further implement the company’s QbD programme.
The course is preapproved as an elective in the Master of Industrial Drug Development (MIND) programme and the Master of Medicines Regulatory Affairs (MRA) programme and open for freelance students who meet the admission criteria. Students who gain admission to courses will receive an invoice and an admission letter.
After completing the course the student must have gained the
following knowledge, skills and competencies:
- summarize the principles of the QbD approach in pharmaceutical development and manufacturing
- demonstrate basic knowledge about risk management, design of experiments and PAT
- demonstrate basic knowledge about the relationship of the QbD approach into design space and further, into the regulatory framework
- apply basic risk analysis and design of experiments techniques into practical cases
identify and suggest suitable process analytical tools for a given manufacturing environment
- work in a multidisciplinary risk management team
- plan and implement basic design of experiments (DoE) approach
suggest a QbD approach for constructing a design space.
The course is organized as an intensive 5-day course and comprises lectures, group discussions, presentations and discussions. In order to emphasize the flow of the process, the course is to a large extent based on the use of cases in both lectures and assignments.
The common course syllabus is a collection of legislation, presentations (hand-outs) and cases, approx. 300 pages.
Applicants must meet the following criteria:
• A relevant bachelor degree or equivalent
• A minimum of 2 years of relevant job experience
• Proficiency in English
- 3 ECTS
- Type of assessment
Written assignmentAn essay based on a selected QbD case and the common course syllabus. The essay must be 8-15 pages.
- All aids allowed
- Marking scale
- passed/not passed
- Censorship form
- No external censorship
Criteria for exam assessment
To pass the exam, the participant must have written a comprehensive and structured report on a selected case in his/hers own words, which is based on relevant literature. This report should clearly demonstrate that the participant has gained:
- at basic level about risk management, design of experiments and PAT
- applying basic risk analysis and design of experiments techniques into practical cases
identifying realistic process analytical tools for a given manufacturing environment
- to work in a multidisciplinary risk management team
- to plan and implement basic design of experiments (DoE) approach
to suggest a QbD approach for constructing a design space.
Part time Master and Diploma courses
- Class Instruction
- Course number
- 3 ECTS
- Programme level
- Part Time Master
DKK 19,900. Fee includes teaching, course materials, and all meals during course and examination.
19-23 August 2019
- 25 participants
- Study Board for the Professionel Master´s Degree Programmes at The Faculty og Health and Medical Science
- Department of Pharmacy
- Faculty of Health and Medical Sciences
- Jukka Rantanen (14-6d786e6e643175647177647168714376787167316e7831676e)
- Poul Egon Bertelsen (5-76747a6a7146726b7533766e6778736734697573)
Staffan Folestad, Professor, Senior Principal Scientist, Astra
Wim Oostra, PhD, Technical Manager, Abbott Healthcare, The Netherlands
Øyvind Holte, PhD, Scientific officer, Norwegian Medicines Agency, Norway
Erik Skibsted, PhD, Principal Scientist, Novo Nordisk A/S, Denmark
Morten Allesø, PhD, Senior Consultant, NNE Pharmaplan, Denmark
Additional speakers may be included.
Are you BA- or KA-student?
Courseinformation of students